Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ +3.23%49 EBITDA Margin % is 1.25% as of Dec. 2025, which is 91% below its 10-year median of 13.71. GuruFocus rates ASX:EZZ with a GF Score™ of 49/100 and a GF Value™ of A$1.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, EZZ Life Science Holdings ranks better than 74.71% on this metric.
EZZ Life Science Holdings (ASX:EZZ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
EZZ Life Science Holdings EBITDA Margin % Related Terms
EZZ Life Science Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EZZ vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) has a EBITDA Margin % of 1.25% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EZZ Life Science Holdings and its competitors. This is 91% below median its historical median of 13.71. Over the past decade, EZZ Life Science Holdings' EBITDA Margin % has ranged from 10.43 to 16.60. According to the industry distribution chart, EZZ Life Science Holdings ranks #238 out of 941 companies in the Biotechnology industry, placing it in the top 25.3%.
Is EZZ Life Science Holdings' EBITDA Margin % too high?
EZZ Life Science Holdings' current EBITDA Margin % of 1.25% is 91% below median its 10-year median of 13.71. Over the past 10 years, this metric has ranged from a low of 10.43 to a high of 16.60. Based on the distribution chart, EZZ Life Science Holdings ranks #238 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #238 out of 941 companies for EBITDA Margin %. This puts EZZ Life Science Holdings in the upper half of its industry. Historically, EZZ Life Science Holdings' own EBITDA Margin % has ranged from 10.43 to 16.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EZZ Life Science Holdings and its competitors. EZZ Life Science Holdings's current EBITDA Margin % is 1.25%, which is 91% below median its own 10-year median of 13.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current EBITDA Margin % is 1.25%, which is 91% below median its 10-year median of 13.71. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current EBITDA Margin % is 1.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
EBITDA Margin %: 1.25% (91% below median its 10-year median of 13.71)
GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score
Get the complete analysis for ASX:EZZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
